Coming Off Ozempic: A 2026 Peptide Transition Guide
What happens when you stop a GLP-1, why most patients regain 60-70% of the weight within a year, and the peptide playbook providers use to hold the line on body composition without staying on Ozempic forever.
In this article
Key Takeaways
- Roughly 60-70% of the weight lost on a GLP-1 is regained within 12 months of stopping, per the STEP-4 and SURMOUNT-4 extension data.
- Up to 40% of the weight lost on a GLP-1 is lean mass — that deficit does not automatically reverse when you stop. Growth-hormone-axis peptides (CJC-1295/Ipamorelin) are the standard provider response.
- For visceral fat regain after stopping a GLP-1, Tesamorelin is the most-targeted peptide — originally approved for HIV-associated lipodystrophy, with clinical visceral-fat reduction data over 12-26 weeks.
- AOD-9604 is the gentler general-fat-loss option for the maintenance phase — peptide-grade prescription versions are sterility-tested and potency-verified, distinct from the supplement-aisle versions.
- Peptides are not GLP-1 substitutes — most do not suppress appetite. They are body-composition tools for the off-GLP-1 phase, not appetite suppressants.
Quick Answer
The post-GLP-1 problem in one paragraph
GLP-1 medications work — semaglutide and tirzepatide produce 15-22% body weight loss in clinical trials. The problem is what happens next. The STEP-4 and SURMOUNT-4 extension trials both show 60-70% of the weight returning within 12 months of stopping. Peptide therapy does not replace the GLP-1; nothing does. What it does is target the three things the GLP-1 leaves behind — lean mass deficit, visceral fat redistribution, and metabolic suppression — with specific tools for each. Tesamorelin for visceral fat. CJC-1295/Ipamorelin for lean mass and recovery. AOD-9604 or MOTS-c for ongoing metabolic support. This guide walks through the playbook providers actually use.
Why Stopping a GLP-1 Is Hard
If you have been on Ozempic, Wegovy, Mounjaro, or Zepbound for 6-18 months and are thinking about coming off — or have already stopped and watched the scale move the wrong direction — you are not alone, and you are not failing the medication. The rebound is mechanistic, not behavioral. The GLP-1 was doing a specific job, and when you stop, that job stops being done.
The 2022 STEP-4 extension trial on semaglutide enrolled patients who had reached their target weight and then stopped the medication. The result: roughly two-thirds of the weight loss came back within a year. The 2023 SURMOUNT-4 data on tirzepatide showed a similar pattern, with rebound starting within the first 8-12 weeks after discontinuation. The conclusion across both trials was the same. GLP-1 weight loss is sustained while the medication is sustained. Off the medication, the body's set point reasserts itself.
This is not a moral failing or a willpower problem. The GLP-1 was suppressing appetite at the receptor level (GLP-1R agonism), slowing gastric emptying, and modulating central reward pathways. When you stop, all three of those mechanisms come back online. Hunger returns. Satiety drops. Food becomes more rewarding. The same biology that made obesity hard to manage before the GLP-1 is still there.
What changes after a GLP-1 cycle is the body composition of the patient. They are now lighter, but they are also potentially leaner-muscled, with a different visceral-fat distribution and a downshifted metabolic rate. That altered baseline is what peptide therapy is positioned to address — not by replacing the GLP-1, but by treating the specific deficits the GLP-1 leaves behind.
The Three Deficits Left Behind
Patients coming off GLP-1s show a recurring trio of issues that providers see again and again. Each has a different mechanism. Each has a different peptide response.
| Deficit | What it looks like | Mechanism | Peptide response | |
|---|---|---|---|---|
| Lean mass loss | Lean mass loss | Strength dropping, looking "smaller" not just thinner, recovery from gym sessions taking longer | Up to 40% of the weight lost on GLP-1 is lean mass; the deficit does not automatically reverse | CJC-1295/Ipamorelin (most common), Sermorelin, Ipamorelin alone |
| Visceral fat redistribution | Visceral fat redistribution | Belly volume increasing faster than overall scale weight; waist measurement creeping up despite stable weight | After GLP-1 discontinuation, regained fat preferentially deposits viscerally in some patients | Tesamorelin (specifically targets visceral adipose tissue) |
| Metabolic suppression | Metabolic suppression | Same calories that maintained weight on GLP-1 now drive regain; resting metabolic rate downshifted | Adaptive thermogenesis and reduced lean mass both lower BMR; mitochondrial function changes during caloric deficit | AOD-9604 (general fat metabolism), MOTS-c (mitochondrial / metabolic flexibility), CJC-1295/Ipamorelin (raises BMR via lean mass support) |
Most patients have all three deficits to varying degrees. The peptide response is rarely a single peptide — it is more often a combination targeting two or three of the deficits simultaneously, run for a defined cycle (typically 8-12 weeks for GH-axis peptides, 12-16 weeks for body-composition peptides), with breaks built in. This is what providers mean when they talk about 'the post-GLP-1 stack.'
The Peptide Playbook
Here are the peptides most frequently prescribed for the post-GLP-1 transition phase, with what each is doing and when it is the right tool. None of these are appetite suppressants — they are body-composition and metabolic-support medications. If appetite return is your primary concern, that is a conversation about whether you should be coming off the GLP-1 at all.
| Peptide | Best for | Cycle length | PeRx pricing | |
|---|---|---|---|---|
| Tesamorelin | Tesamorelin | Visceral fat reduction (the most-targeted peptide for post-GLP-1 belly volume) | 12-26 weeks | From $299 / month supply |
| CJC-1295/Ipamorelin | CJC-1295/Ipamorelin | Lean mass retention, deeper sleep, recovery from resistance training | 8-12 weeks | From $229 / month supply |
| AOD-9604 | AOD-9604 | General fat metabolism without HGH systemic effects (gentler than Tesamorelin) | 12-16 weeks | From $229 / month supply |
| MOTS-c | MOTS-c | Mitochondrial / metabolic flexibility, exercise capacity at altitude or in deficit | 8-12 weeks | From $229 / month supply |
| AOD-9604/MOTS-c combo | AOD-9604/MOTS-c combo | Combined fat metabolism + mitochondrial support in a single vial | 12-16 weeks | From $299 / month supply |
| BPC-157 | BPC-157 | Gut healing for patients with lingering GI inflammation from GLP-1 use | 4-8 weeks | From $229 / month supply |
A note on pricing
PeRx is not a subscription service. Each vial is a 1-month supply, and you order when you need to within a 100-day prescription cycle (up to 3 months of supply per cycle). After the cycle ends, a brief provider check-in opens the next 100 days. The "from $X/month" pricing reflects per-vial cost, not a recurring monthly charge.
Most patients run two peptides at once during the transition — typically Tesamorelin or AOD-9604 paired with CJC-1295/Ipamorelin. The first is targeting fat composition; the second is preserving lean mass. Running both simultaneously costs more upfront than a GLP-1 prescription but for a defined cycle (12-16 weeks), then off. Total cost for a typical 12-week post-GLP-1 cycle: roughly $1,500-$2,000 across both peptides combined, vs. continued indefinite GLP-1 use at $900-$1,400/month.
Timing the Transition
The most common provider recommendation is to begin peptide therapy 2-4 weeks before your final GLP-1 dose, so the peptide protocol is fully active before you stop the GLP-1. This matters more for CJC-1295/Ipamorelin and Tesamorelin (both of which take 2-4 weeks to register their primary effects) than for AOD-9604 or MOTS-c (which are flexible on timing).
A typical 16-week transition protocol
Weeks -4 to -1
Still on GLP-1 (final taper doses). Begin CJC-1295/Ipamorelin and either Tesamorelin or AOD-9604. Sleep effects from CJC/Ipa typically register around week 2-3. Begin or maintain resistance training program — this is non-negotiable for the lean mass goal.
Week 0 (final GLP-1 dose)
Last GLP-1 injection. Continue peptide protocol unchanged. Do not stop both medications simultaneously — let the GLP-1 wash out (roughly 4-5 weeks for semaglutide) while peptides remain in place.
Weeks 1-4 (post-GLP-1)
Appetite returns. This is the highest-risk window for rebound behaviors. Continue peptide protocol. Track protein intake (1.6-2.2 g/kg lean mass). Track resistance training adherence. Body composition changes from peptides are not yet measurable; the protocol is doing maintenance work, not visible work.
Weeks 5-12
Peptide effects compound. Tesamorelin visceral fat changes typically measurable by week 8-12. CJC-1295/Ipamorelin lean mass and recovery effects steady. Body composition (DEXA, InBody, or just waist + grip strength) showing meaningful change.
Weeks 13-16
Cycle wind-down. Discuss with provider whether to continue, switch to a maintenance-dose peptide, or take a break. Most providers recommend at least a 4-6 week break before starting another GH-axis cycle.
What peptides cannot do
The honest framing: peptides do not suppress appetite. The hunger returning post-GLP-1 is real and is not what these tools address. If you are coming off a GLP-1 and the question is 'how do I not eat more,' the answer is behavioral — protein intake, sleep, stress management, structured eating windows — not pharmacological. Peptides are working on the body composition side of the equation, not the appetite side. Patients who expect peptides to act like a milder GLP-1 are usually disappointed. Patients who expect peptides to support the metabolic and lean-mass changes during a defined off-GLP-1 window usually are not.
Cost: GLP-1 vs Peptide Therapy
For patients staring at indefinite GLP-1 cost, the math on a defined peptide transition cycle often favors peptides. The honest comparison:
| Therapy | Monthly cost | Cycle length | Total annual cost | |
|---|---|---|---|---|
| Brand-name GLP-1 (retail) | Brand-name GLP-1 (retail) | $900–$1,400 per month | Indefinite | $10,800–$16,800 |
| Brand-name GLP-1 (with insurance) | Brand-name GLP-1 (with insurance) | $200–$500 per month | Indefinite | $2,400–$6,000 |
| Compounded GLP-1 (where available) | Compounded GLP-1 (where available) | $200–$500 per month | Indefinite | $2,400–$6,000 |
| PeRx post-GLP-1 peptide cycle (Tesamorelin + CJC/Ipa) | PeRx post-GLP-1 peptide cycle (Tesamorelin + CJC/Ipa) | $525 per month supply (combined) | 12-16 weeks | $1,575–$2,100 per cycle, then off |
Compounded peptides are not insurance-covered for the same reason most compounded medications are not — they fall outside standard formularies. Many HSA and FSA cards do work with a valid prescription, depending on the plan administrator and the prescribing diagnosis. The bigger structural difference is that peptide cycles are finite. A 12-16 week cycle has a defined end. GLP-1 use, in the current treatment paradigm, does not.
For patients who want to come off the GLP-1 entirely, a defined peptide cycle followed by behavioral maintenance (protein, training, sleep, eating windows) is the path most providers recommend. For patients who want to stay on a low-dose GLP-1 indefinitely, peptides can run alongside — that is a different conversation, but it is a viable one. We covered the parallel-use case in our muscle loss on GLP-1 guide.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
MOTS-c: The Complete Guide to the Mitochondrial Exercise Peptide
Your mitochondria aren't just making energy. They're sending messages. MOTS-c is one of their most important signals: a 16-amino-acid peptide your body produces during exercise that regulates metabolism, insulin sensitivity, and physical performance. It declines as you age. It was only discovered in 2015. And it may represent an entirely new frontier in metabolic medicine.
AOD-9604: The Fat-Burning Fragment That Came From Growth Hormone
Growth hormone burns fat. It also raises blood sugar, swells joints, and can trigger abnormal growth. In 1993, an Australian biochemist isolated the 16 amino acids responsible for fat metabolism and nothing else. That fragment became AOD-9604. It sailed through early clinical trials, stumbled at Phase IIb, earned FDA safety clearance, and is now finding a second life through compounding pharmacies and emerging joint-health research.
Tesamorelin: The Only FDA-Approved GHRH Analog for Visceral Fat Reduction
Most peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.
Ready to plan the transition?
Take our 5-minute health assessment to find the peptide protocol that fits your post-GLP-1 goals. A licensed provider reviews every intake. Approved orders ship overnight, refrigerated, ready to use.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.